Literature DB >> 12496425

Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.

Stephen D Hess1, Nejat K Egilmez, Nicola Bailey, Timothy M Anderson, Edith Mathiowitz, Steven H Bernstein, Richard B Bankert.   

Abstract

By implanting nondisrupted pieces of human lung tumor biopsy tissues into SCID mice, it has been possible to establish viable grafts of the tumor, as well as the tumor-associated microenvironment, including inflammatory cells, fibroblasts, tumor vasculature, and the extracellular matrix. Using this xenograft model, we have evaluated and characterized the effects of a local and sustained release of human rIL-12 (rhIL-12) from biodegradable microspheres. In response to rhIL-12, the human CD45+ inflammatory cells present within the xenograft mediate the suppression or the complete arrest of tumor growth in SCID mice. Analysis of the cellular events reveals that human CD4+ and CD8+ T cells are induced by rhIL-12 to produce and secrete IFN-gamma. Serum levels of human IFN-gamma in mice bearing rhIL-12-treated tumor xenografts correlate directly with the degree of tumor suppression, while neutralizing Abs to human IFN-gamma abrogate the IL-12-mediated tumor suppression. Gene expression profiling of tumors responding to intratumoral rhIL-12 demonstrates an up-regulation of IFN-gamma and IFN-gamma-dependent genes not observed in control-treated tumors. Genes encoding a number of proinflammatory cytokines, chemokines (and their receptors), adhesion molecules, activation markers, and the inducible NO synthase are up-regulated following the introduction of rhIL-12, while genes associated with tumor growth, angiogenesis, and metastasis are decreased in expression. NO contributes to the tumor killing because an inhibitor of inducible NO synthase prevents IL-12-induced tumor suppression. Cell depletion studies reveal that the IL-12-induced tumor suppression, IFN-gamma production, and the associated changes in gene expression are all dependent upon CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496425     DOI: 10.4049/jimmunol.170.1.400

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.

Authors:  Michael J Robertson; Hua-Chen Chang; David Pelloso; Mark H Kaplan
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

3.  Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Authors:  Sandra J Yokota; John G Facciponte; Raymond J Kelleher; Leonard D Shultz; Jenni L Loyall; Robert R Parsons; Kunle Odunsi; John G Frelinger; Edith M Lord; Scott A Gerber; Sathy V Balu-Iyer; Richard B Bankert
Journal:  Cancer Immun       Date:  2013-05-31

4.  Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression.

Authors:  Stephanie K Watkins; Bing Li; Katharine S Richardson; Kimberly Head; Nejat K Egilmez; Qun Zeng; Jill Suttles; Robert D Stout
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

5.  Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Imelda S Quinlin; Khaliquzzaman A Samad; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Clin Immunol       Date:  2009-09-16       Impact factor: 3.969

6.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Authors:  Michelle R Simpson-Abelson; Vivek S Purohit; Wing Man Pang; Vandana Iyer; Kunle Odunsi; Todd L Demmy; Sandra J Yokota; Jenni L Loyall; Raymond J Kelleher; Sathy Balu-Iyer; Richard B Bankert
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

7.  Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Authors:  Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-03-24       Impact factor: 5.191

8.  IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Authors:  Elizabeth W Sorensen; Scott A Gerber; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2010-01-08       Impact factor: 5.422

Review 9.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

10.  Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.

Authors:  T M Anderson; S D Hess; N K Egilmez; C E Nwogu; J M Lenox; R B Bankert
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.